4 November 2024
Physiomics plc
("Physiomics" or the "Company")
Senior Management
Announcement
Physiomics plc (AIM: PYC), a leading
mathematical modelling, data science and biostatistics company
supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce the hiring this week of
a new senior member of its team, Dr Mark Davies, as Head of
Quantitative Pharmacology and Data Science.
Dr Mark Davies brings over 20 years' experience
in drug development, both from the perspective of working within
major pharmaceutical companies (such as AstraZeneca) as well as
from within service businesses supporting biopharma companies
worldwide. During this time, his roles have spanned a variety of
different disease areas and phases of drug discovery and
development. His main areas of experience are within computational
biology and data informatics bringing a collaborative approach to
improve how companies work with and analyse datasets from different
sources. He has numerous peer-reviewed publications and broad
experience in experimental techniques, informatics and their
applications to modelling, helping to answer critical questions in
drug discovery. More recently, he has worked in business
development roles for state-funded (Medicines Discovery Catapult)
and multiple Contract Research Organisations (service providers)
across Europe, bringing a consultative approach to the utility of
informatics-based approaches to questions in the healthtech and
pharmaceutical industry. Mark has a PhD in Biological Sciences,
from the University of Warwick, UK, and B.Sc in Biochemistry from
University of Bath, UK.
This new senior role will be
responsible for the Company's Modelling, Simulation and Data
Science service line and will work closely with the CEO and Board
on setting its overall strategic direction. Dr Davies' focus will
be to drive growth and operational excellence in this service area.
He will work closely with the Head of Business Development to
expand our services and market reach, helping to accelerate
conversion of new opportunities into contracts. From an operational
standpoint, the role will provide operational governance and
line-management of the technical team, ensuring efficient delivery
of high-quality consultancy projects.
Dr Peter
Sargent, CEO, commented: "We are delighted to welcome Mark to our
team. We feel that his unique mix of technical and commercial
experience spanning across modelling & simulation, data science
and drug development, he will be a great addition to the
Company".
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Limited (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines expertise
across Modelling & Simulation, Biostatistics, Data Science and
Bioinformatics, together with deep biology expertise, to help
biotech and pharma companies streamline their drug development
journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and
clinical studies. Through use of cutting-edge computational tools,
bespoke models and our proprietary Virtual Tumour technology, the
Physiomics team has informed the development of over 100 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.